Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

April 20, 2026
Pharmidex is pleased to announce that Ian Knowles and Janette Dalay Robertson , will be attending TARGET TO PATIENT 2026 (T2P26) on Monday 20th – Tuesday 21st April 2026 at the Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK. They look forward to meeting founders, investors and biotech leaders to discuss drug discovery, translational partnerships and life science investment opportunities. Feel free to catch them for a chat!
FROM DISCOVERY TO DISTRIBUTION
April 16, 2026
Pharmidex is pleased to announce that Martin Barrett , Head of Business Development, will be attending FROM DISCOVERY TO DISTRIBUTION – Making Pharmaceuticals 2026 on 21–22 April 2026 at the Coventry Building Society Arena, UK. Martin looks forward to meeting pharma innovators, formulation scientists, manufacturing leaders and strategic partners to discuss drug discovery, development, translational science, and end-to-end pharmaceutical solutions. If you’re attending, feel free to stop by for a chat and explore how Pharmidex can support your programmes from discovery through development.
April 15, 2026
Pharmidex will be attending Swiss Biotech Day 2026 on 4–5 May 2026 at the Congress Center Basel, Switzerland. We look forward to meeting founders, investors, biotech leaders and scientific partners to discuss drug discovery, translational development and strategic R&D opportunities. Feel free to catch us for a chat!
More Posts